Result:Weak· Market: Crashed#Margin squeeze
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 72.94 | 2.9% | 11.6% |
| Total Income | 73.41 | 4.9% | 12.1% |
| Expenditure | 69.97 | 8.2% | 8.5% |
| PBT | 3.44 | 279.9% | 51.0% |
| Net Profit | 1.84 | 435.0% | 58.0% |
| OPM | 12.50% | 6.96pp | 1.70pp |
| NPM | 2.51% | 2.06pp | 2.74pp |
| EPS | 8.75 | 507.6% | 36.4% |
Revenue fell 11.6% YoY and adjusted PAT dropped 58% with both OPM (14.2%→12.5%) and NPM (5.25%→2.51%) compressing, a broad-based decline in the pharma company's core growth and profitability.
Informational and educational content only. Not investment advice.